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regulating nucleic acid target. In its activated state the functional nucleic acid can bind to its target to carry out
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FUNCTIONAL NUCLEIC ACID PROBES AND 
USES THEREOF 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority to US. Provisional Patent 
Application No. 60/275,695 ?led on Mar. 15, 2001 Which is 
hereby incorporated by reference in its entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
The United States Government may have certain rights in 
this invention pursuant to Grant Number W-7405-Eng-82 
from the Department of Energy, and National Institute of 
Health Grant No. R43CA102816. 
REFERENCES 
Several patents and other publications are referenced 
herein. Full citations for these publications are provided 
beloW. The disclosures of these publications are hereby 
incorporated herein by reference in their entirety, unless 
otherWise noted. 
BACKGROUND OF THE INVENTION 
Detection of nucleic acids is the cornerstone of biotech 
nology and molecular biology. Single-base pair mutations in 
a gene can be detected With great speci?city and accuracy. 
The level of expression of a particular gene can be measured 
by detecting mRNA expression levels for the gene in a cell. 
Knowledge about the location, sequence, regulation, and 
expression of a gene yields information critical to the 
diagnosis and treatment of a variety of diseases. 
Nucleic acid probes are typically short nucleic acid 
sequences used to detect, amplify, and quantify DNA and 
RNA for diagnostic and therapeutic applications. They are 
designed to speci?cally hybridiZe With particular comple 
mentary target nucleic acid sequences. Nucleic acid probes 
are labeled With radioactive or ?uorescent tags in order to 
detect the presence or absence of the target nucleic acid 
sequence using a variety of techniques (e.g., ?uorescent 
in-situ hybridiZation, Southern blot, Northern blot, and 
chromatography). While these techniques are useful for 
detecting the presence or absence of particular target 
sequences, their sensitivity depends on the amount of target 
nucleic acid present in the sample. Furthermore, living cells 
cannot be analyZed using these techniques since samples 
must be extracted, and ?xed or froZen prior to analysis. 
In order to increase the sensitivity of nucleic acid detec 
tion techniques, labeled probes are combined With ampli? 
cation processes, such as PCR, to amplify and detect nucleic 
acids. The combination of probes and ampli?cation pro 
cesses has been especially useful in forensic applications 
Where the nucleic acid of interest may only be present in 
extremely small quantities. Many disease conditions are 
diagnosed by comparing the amount of mRNA produced in 
a normal cell to a diseased cell. For example, increased 
expression of an oncogene may indicate the presence of a 
tumor cell. Ampli?cation techniques, such as PCR, are 
non-linear and exponentially increase the amount of nucleic 
acid present in a sample. Thus, the amount of nucleic acid 
present in a sample subject to PCR is not representative of 












Nucleic acid ampli?cation techniques are of limited use for 
quantifying the amount of nucleic acid present in a sample. 
Previously, nucleic acids Were thought to be a medium 
solely for storing, transporting, processing, and expressing 
genetic information. Recently, hoWever, nucleic acids 
capable of additional functions have been identi?ed. These 
“functional nucleic acids” can, for example, catalyZe reac 
tions or bind speci?cally to particular targets. The three 
dimensional structure of functional nucleic acids provides 
the speci?city necessary to bind other compounds much like 
the three-dimensional structure of an enZyme determines its 
speci?city for a substrate. The small siZe, speci?city, and 
ease of manipulation of nucleic acids can noW be applied to 
functions traditionally associated With proteins (e.g., cataly 
sis, receptors, and antibodies). 
Molecular beacons are functional single-stranded DNA 
probes that can report the presence of speci?c nucleic acids. 
Molecular beacons are stem-loop shaped molecules contain 
ing a nucleotide sequence in the loop portion of the molecule 
complementary to a target DNA or RNA. Molecular beacons 
are labeled on one end With a ?uorescent molecule and on 
the other With a quenching molecule. In its native hairpin 
structure, the quenching molecule is in close proximity With 
the ?uorescent molecule and absorbs the light emission of 
the ?uorescent molecule. When the complementary nucle 
otide sequence on the molecular beacon loop binds its target 
molecule, the molecular beacon undergoes a conformational 
change that opens up the stem-loop structure and causes the 
?uorescent molecule and the quenching molecule to move 
aWay from each other. The light emission from the ?uores 
cent molecule is no longer quenched and the signal can be 
detected. 
Molecular beacons are of limited use in generating ampli 
?ed signals. The ?uorescent signal of a molecular beacon is 
an integral part of the molecular beacon. Thus, the ?uores 
cent molecule of the molecular beacon can generate only 
one signal in the presence of its target. The signal cannot be 
further ampli?ed or altered by use of, for example, second 
ary labeled antibodies. The Weak, unampli?ed signal gen 
erated by the molecular beacon is not able to penetrate living 
tissue su?iciently for use in non-invasive imaging. 
Aptamers are functional synthetic nucleic acids optimiZed 
for high-a?inity binding to targets (e.g., nucleic acids, pro 
teins, and chemical compounds). Unlike naturally occurring 
nucleic acids, Which are optimiZed With respect to transfer of 
genetic information, aptamers are selected on the basis of 
their ability to speci?cally bind their ligand. Systematic 
Evolution of Ligands by Exponential Enrichment (SELEX) 
is a process of selecting aptamers directed to a chosen 
ligand. See Hermann and Patel, Science 287, pp 82(L825 
(2000); US. Pat. Nos. 5,475,096, 5,595,877, 5,660,985, and 
6,180,348. The SELEX process selects aptamers by screen 
ing random sequence libraries, retaining sequences that bind 
the chosen target molecule, and repeating the cycle With 
increasing levels of binding stringency. The selected 
aptamer is capable of binding a chosen target but not other 
molecules. 
RiboZymes are functional nucleic acid molecules With 
enZymatic capabilities, including the ability to cleave 
nucleic acid molecules in a sequence-speci?c manner. The 
three-dimensional structure of a riboZyme, like a protein 
enZyme, determines the speci?city of its interaction With a 
particular target. Allosteric riboZymes are riboZyme nucleic 
acid constructs having a riboZyme portion and an antisense 
nucleic acid portion. The activation of the riboZyme is 
regulated by the binding of the antisense nucleic acid to a 
complementary nucleic acid target. In the absence of the 
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antisense target, the riboZyme is inactive. In the presence of 
the antisense target, the riboZyme is activated and capable of 
catalyzing a reaction. 
Allosteric riboZymes may also include an attenuator 
sequence that binds completely or partially to the antisense 
nucleic acid portion as Well as to the riboZyme portion. The 
“overlapping” attenuator sequence and the antisense target 
sequence compete for the binding site on the antisense 
sequence. In the presence of a suf?cient amount of the 
antisense target sequence, the attenuator nucleic acid strand 
is displaced from the antisense sequence and the riboZyme 
is able to fold into its active conformation. HoWever, strand 
displacement of the attenuator by the antisense target 
sequence has signi?cant disadvantages. For example, the 
attenuator sequence must be designed to bind both the 
riboZyme and the antisense target sequence. This require 
ment limits the availability of compatible riboZyme-anti 
sense sequence combinations. In addition, the antisense 
target sequence must compete for an overlapping binding 
site on the antisense sequence. Therefore, a relatively large 
quantity of the antisense target sequence is required in order 
to successfully displace the attenuator from the antisense 
sequence, thus resulting in reduced sensitivity of the probe. 
It should be appreciated that there is a need for highly 
sensitive, functional nucleic acid probes capable of being 
activated to bind a target only in the presence of a particular 
ligand Without being subject to foregoing limitations. 
BRIEF SUMMARY OF THE INVENTION 
The present invention provides nucleic acid probes for 
activating functional nucleic acids in the presence of a 
particular target. It has been unexpectedly discovered that 
nucleic acid probes having at least one functional nucleic 
acid (e.g., an aptamer or riboZyme), at least one regulating 
nucleic acid (e.g., antisense nucleic acid or aptamer), and at 
least one attenuator, are activated only in the presence of a 
regulating nucleic acid target. The modular nature of the 
nucleic acid probes provides great ?exibility in designing 
custom probes using a variety of functional nucleic acids, 
regulating nucleic acids, and attenuators. 
In one embodiment the functional nucleic acid probe is 
maintained in an inactive state by binding at least a portion 
of the functional nucleic acid to an attenuator. When the 
probe’s regulating nucleic acid binds to its target, the 
conformation of the functional nucleic acid is modi?ed 
resulting in removal of the attenuator and activation of the 
functional nucleic acid. The activated functional nucleic 
acid can then bind to its target. In other embodiments of the 
invention, the functional nucleic acid probes detects and 
quanti?es nucleic acids in solution, in cells (e.g., ?xed, 
froZen, and living cells), and in vivo for non-invasive 
imaging. The invention further provides functional nucleic 
acid probes that bind to a variety of signaling molecules 
(e. g., labeled proteins, labeled nucleic acids, and ?uorescent 
compounds) and functional nucleic acid probes that catalyZe 
reactions (e.g., site-speci?c cleavage of DNA or RNA). 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 depicts an exemplary functional nucleic acid probe 
(SEQ ID NO: 5) including a functional nucleic acid (SEQ ID 
NO: 1), a regulating nucleic acid (SEQ ID NO: 2), and an 
attenuator (SEQ ID NO: 3). 
FIGS. 2a and 2b depict alternate structural conformations 
adopted by the functional nucleic acid probe (SEQ ID NO: 












target. The attenuator (oval) (SEQ ID NO: 3) is shoWn 
bound to the DNA-ATP aptamer (rectangle) (SEQ ID NO: 
1). 
FIG. 3 depicts the structure adopted by the functional 
nucleic acid probe (SEQ ID NO: 5) of FIG. 1 in the presence 
of the regulating nucleic acid target (SEQ ID NO: 4). The 
functional nucleic acid (SEQ ID NO: 1) is shoWn in its 
active conformation. The regulating nucleic acid (SEQ ID 
NO: 2) is shoWn bound the regulating nucleic acid target 
(SEQ ID NO: 4). 
FIG. 4 demonstrates that the functional nucleic acid probe 
of FIG. 1 is activated only in the presence of the regulating 
nucleic acid target. 
FIG. 5 shoWs a linear relationship betWeen the activity of 
the functional nucleic acid probe of FIG. 1 and the amount 
of regulating nucleic acid target. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Reference Will noW be made in detail to the presently 
preferred embodiments of the invention, Which serve to 
explain the principles of the invention. It is to be understood 
that the application of the teachings of the present invention 
to a speci?c problem or environment Will be Within the 
capabilities of one having ordinary skill in the art in light of 
the teachings contained herein. 
The present invention provides functional nucleic acid 
probes, Which, in one embodiment, include at least one 
functional nucleic acid, at least one regulating nucleic acid, 
and at least one attenuator. The functional nucleic acid is 
capable of binding to a speci?c target in order to carry out 
a desired function (e.g., catalyZe a reaction, generate a 
signal, or cleave a nucleic acid). The regulating nucleic acid 
and the attenuator regulate the activity of the functional 
nucleic acid in response to environmental conditions (e.g., 
expression of an mRNA, the presence of an oncogenic 
protein, or the presence of a toxin). Preferably, the regulating 
nucleic acid is capable of activating the functional nucleic 
acid only When the regulating nucleic acid is bound to a 
regulating nucleic acid target. The attenuator preferably 
binds only to the functional nucleic acid, and maintains the 
functional nucleic acid in an inactive state so long as the 
regulating nucleic acid is not bound to the regulating nucleic 
acid target. The invention further provides methods of 
activating a functional nucleic acid to bind to a target by 
providing a functional nucleic acid, a regulating nucleic 
acid, and an attenuator Wherein binding of the regulating 
nucleic acid to the regulating nucleic acid target induces the 
removal of the attentuator from the functional nucleic acid 
and activates the functional nucleic acid to bind its ligand. 
In one embodiment, the functional nucleic acid forms an 
H-type pseudoknot in Which the bases in a loop hybridize 
With a sequence from a distal single-stranded nucleic acid 
region. The pseudoknot structure of the functional nucleic 
acid is stable at temperatures normally used for hybridiza 
tion of nucleic acids. In its pseudoknot con?guration, the 
functional nucleic acid stem can unravel slightly to relieve 
the strain created in the functional nucleic acid loop by 
hybridiZation With the attenuator. This unraveling further 
distorts the functional nucleic acid and further decreases the 
probability that it Will bind its target in the inactive state. 
In another embodiment of the invention, the functional 
nucleic acid probe may comprise multiple functional nucleic 
acids. Each functional nucleic acid can speci?cally bind to 
the same or different target. For example, one functional 
nucleic acid may be an aptamer Which speci?cally binds to 
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a ?uorescently labeled target in the presence of RAS onco 
gene mRNA. Another functional nucleic acid may be a 
riboZyme Which inactivates the RAS oncogene mRNA. 
These exemplary multi-functional nucleic acid probes can 
carry out tWo independent functions in the presence of a 
single target. In another embodiment of the invention, the 
functional nucleic acid probe comprises multiple regulating 
nucleic acids each linked to a functional nucleic acid. 
Alternatively, the functional nucleic acid probes comprise 
multiple functional nucleic acids, regulating nucleic acids, 
and attenuators. Multi-functional probes can be applied 
simultaneously to diagnose, monitor, and treat a diseased 
cell in the presence of one or more corresponding signals. 
“Ampli?cation,” as used herein, refers to the production 
of additional copies of a nucleic acid sequence and is 
generally carried out using PCR technologies Well knoWn in 
the art. The terms “antagonist” or “inhibitor,” as used herein, 
refer to a molecule Which, When bound to a target, blocks or 
modulates the biological or immunological activity of the 
target. Antagonists and inhibitors may include proteins, 
nucleic acids, carbohydrates, or any other molecules Which 
bind to the target either covalently or non-covalently. 
The term “antisense,” as used herein, refers to nucleotide 
sequences Which are complementary to a speci?c DNA or 
RNA sequence. The term “antisense strand” means a nucleic 
acid strand that is complementary to the “sense” strand. 
Antisense molecules may be produced by any method, 
including synthesis by ligating the gene(s) of interest in a 
reverse orientation to a viral promoter Which permits the 
synthesis of a complementary strand. Once introduced into 
a cell, this transcribed strand combines With natural 
sequences produced by the cell to form duplexes. These 
duplexes then block further transcription or translation. 
As used herein, “attenuator” refers to a molecule or 
compound capable of interfering With the activity of a 
functional nucleic acid When bound to the functional nucleic 
acid. 
The terms “complementary” or “complementarity,” as 
used herein, refer to the binding of polynucleotides under 
permissive salt and temperature conditions by base-pairing. 
For example, the sequence “A-G-T” binds to the comple 
mentary sequence “T-C-A”. Complementarity betWeen tWo 
single-stranded molecules may be “partial,” in Which only 
some of the nucleic acids bind, or it may be complete When 
total complementarity exists betWeen the single stranded 
molecules. The degree of complementarity betWeen nucleic 
acid strands has signi?cant effects on the ef?ciency and 
strength of hybridiZation betWeen nucleic acid strands. This 
is of particular importance in ampli?cation reactions, Which 
depend upon binding betWeen nucleic acid strands. 
As used herein, “functional nucleic acid” means a nucleic 
acid With the ability to bind to a speci?c target only When the 
nucleic acid is in a particular “activated” structural confor 
mation. 
“Nucleic acid sequence,” as used herein, refers to an 
oligonucleotide, nucleotide, or polynucleotide, and frag 
ments or portions thereof, and to DNA or RNA of genomic 
or synthetic origin Which may be single- or double-stranded, 
and represent the sense or antisense strand. 
As used herein, “regulating nucleic acid” refers to a 
nucleic acid capable of binding to a target and, When so 
bound, activating a functional nucleic acid. 
The terms “speci?c binding” or “speci?cally binding,” as 
used herein, in reference to the interaction of a nucleic acid 
With its target or ligand, mean that the interaction is depen 
dent upon the presence of a particular structure (i.e., the 












the nucleic acid recogniZes and binds to a speci?c structure 
(e.g., nucleic acid, protein, and compound). 
The probes of the present invention comprise functional 
nucleic acids capable of binding to a speci?c target. The 
functional nucleic acids are preferably single-stranded 
nucleic acids, Which can fold into three-dimensional struc 
tures (conformations) forming binding regions, pockets, and 
other secondary or tertiary surfaces on the molecule. The 
binding site of the activated functional nucleic acid forms a 
highly speci?c complex With a particular target molecule. 
Functional nucleic acids include, but are not limited to, 
aptamers and riboZymes. 
FIG. 1 illustrates a functional nucleic acid probe 1 in 
accordance With a preferred embodiment of the invention. 
With reference to FIG. 1, an exemplary functional nucleic 
acid probe 1 is shoWn. Functional nucleic acid probe 1 
comprises a functional nucleic acid 2, a regulating nucleic 
acid 3, and an attenuator 4. The components comprising the 
exemplary functional nucleic acid probe 1 may be contigu 
ous and cis-aligned, as shoWn in FIG. 1. The sequence of 
attenuator 4 is complementary to at least a portion of 
functional nucleic acid 2. 
FIGS. 2a and 2b illustrate alternative inactive structural 
conformations adopted by functional nucleic acid probe 1 in 
the absence of a regulating nucleic acid target. The altema 
tive inactive conformations Were determined using Mfold, a 
softWare application used to predict the three-dimensional 
conformation of nucleic acid molecules. See A. E. Walter, D. 
H. Turner, J. Kim, M. H. Lyttle, P. Muller, D. H. MatheWs 
and M. Zuker, Coaxial stacking of helixes enhances binding 
of oligoribonucleolides and improves predictions of RNA 
folding, Proc. Natl. Acad. Sci. USA 91, 9218*9222 (1994). 
FIG. 2a depicts a presently preferred conformation in 
Which attenuator 4 is hybridiZed solely to functional nucleic 
acid 2. Regulating nucleic acid 3 forms a loop structure in 
betWeen functional nucleic acid 2 and attenuator 4. The 
?lled circles shoW C-G hydrogen bonds and the open circles 
shoW A-T or non-Watson/Crick hydrogen bonds. 
FIG. 3 depicts the activated structure of functional nucleic 
acid probe 1. Nucleic acid target 5 binds to antisense 
sequence 3. Attenuator 4 is separated from DNA-ATP 
aptamer 2 by the Waston-Crick double-stranded complex of 
the antisense sequence 3 and nucleic acid target 5. DNA 
ATP aptamer 2 is folded in its active con?rmation folloWing 
the binding of nucleic acid target 5 to antisense sequence 3. 
In one embodiment, the functional nucleic acid probe 
binds its target after hybridiZation of the regulating nucleic 
acid target mRNA With the regulating nucleic acid. In 
another embodiment, a signaling mechanism (e.g., a ?uo 
rescent label or radionuclide) is conjugated With the func 
tional nucleic acid target. Because the signaling mechanism 
is linked to the target but does not participate in the 
activation of the functional nucleic acid or contribute to 
recognition of or binding of the functional nucleic acid to its 
target, many different signal mechanisms can be exploited 
(e.g., ?uorescence, radioactivity, chemiluminescence, and 
color signals). Furthermore, the signal generated by the 
binding of the functional nucleic acid probe to its labeled 
target can be ampli?ed by a variety of currently available 
strategies Well knoWn in the art (e.g., use of a secondary 
labeled antibody, a labeled aptamer, or a tyramide detection 
system). 
Functional nucleic acid probes comprised of nucleic acid 
can be generated in situ from a vector, such as vectors used 
in gene therapy. Thus, functional nucleic acid probes can be 
expressed in a desired cell or tissue by using an appropriate 
vector to express the probe in a desired location. Such 
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targeted functional nucleic acid probes can be used for 
signaling gene expression in a particular cell type or target 
ing a diseased cell for killing or inactivation. In addition, 
expression of the functional nucleic acid probe can be placed 
under the control of an inducible promoter thus providing 
additional regulation of the probe. For example, expression 
of a functional nucleic acid probe designed to inactivate the 
expression of an oncogene can be induced by a promoter 
sensitive to the expression of an oncogenic protein. 
In one embodiment of the invention, the functional 
nucleic acid is an aptamer capable of binding to a target 
molecule. Aptamers are nucleic acids that bind ligands With 
high speci?city and high af?nity and can be used, for 
example, to inhibit or interfere With the activity of nucleic 
acid or protein. Preferably, the af?nity of an aptamer for its 
target is in the nanomolar range. Suitable aptamers can be 
selected using various techniques knoWn in the art, such as 
“systematic evolution of ligands by exponential enrichment” 
or “SELEX”. Tuerk and Gold, Science 249, 505 (1990); 
Ellington and SZostak, Nature 346, 818 (1990). In one 
embodiment, the aptamer forms a stem-loop structure in 
Which the bases in the loop form the binding region for 
interaction With a target. 
Aptamers can be designed to bind a variety of targets 
(e. g., proteins, nucleic acids, and compounds). For example, 
aptamers capable of binding proteins associated With a 
variety of diseases have recently been isolated. Sun, Curr 
Opin Mol Ther, 2(1), 100*105 (Feb. 2, 2000). These protein 
binding aptamers are used as antagonists and inhibit physi 
ological functions associated With the protein target. Id. 
Aptamers capable of binding compounds such as theophyl 
line, FMN, AMP, arginine, citruline, tobramycin, neomycin 
B have also been isolated and characteriZed. Hermann and 
Patel, Science, 287, 820*825 (2000). Aptamers can also be 
modi?ed to increase their resistance to nucleases that may be 
encountered in cells or the bloodstream. Sun, Curr Opin Mol 
Ther, 2(1), 100*105 (Feb. 2, 2000). For example, modifying 
2' OH groups of the nucleotide bases of an aptamer to F or 
NH2 increases the half-life of an aptamer in blood. Id. 
Alternatively, aptamers can be attached to higher Weight 
delivery vehicles to increase their resistance to nucleases or 
antibodies. Aptamers can be delivered to cells by a variety 
of techniques including, but not limited to, expression 
vectors, liposomes, viral vectors, and cell fusion. 
In another embodiment of the invention, the functional 
nucleic acid is a riboZyme or deoxyriboZyme (“nucleic acid 
enzymes”). Nucleic acid enZymes are naturally-occurring or 
synthetic nucleic acid structures capable of catalyZing cleav 
age of nucleic acid in a site-speci?c manner. Like aptamers 
and protein enZymes, nucleic acid enZymes form three 
dimensional structures, Which speci?cally interact With their 
substrates. Synthetic nucleic acid enZymes can be isolated 
through in vitro selection, in vivo selection, and in vitro 
evolution procedures. Rossi and Couture, Intracellular 
Ribozyme Applications: Principles and Protocols, (HoriZon 
Press, July 1999). 
The probes of the present invention comprise regulating 
nucleic acids for regulating the activity of a functional 
nucleic acid. Regulating nucleic acids serve as molecular 
sWitches for turning on or activating functional nucleic acids 
in the presence of speci?c targets. For example, With refer 
ence to the above-mentioned oncogene experiment, When an 
expressed oncogenic mRNA is present in the cell and binds 
to and forms a duplex With a regulating nucleic acid, the 
binding energy of the regulating nucleic acid/mRNA duplex 
forces the attenuator to be removed from the functional 












functional nucleic forms its active, three-dimensional con 
formation and, for example, inactivate an oncogenic protein. 
Alternatively, the functional nucleic acid can be activated to 
bind to a labeled target molecule and entrap the label 
associated With the target thus identifying the presence of a 
cell expressing the oncogene. In another embodiment, the 
functional nucleic acid can be activated to kill the cell 
expressing the oncogene. Regulating nucleic acids provide a 
highly sensitive and speci?c signal in the presence of other 
targets. The functional nucleic acid probes of the invention 
may comprise one or more regulating nucleic acids. 
The regulating nucleic acid is preferably of suf?cient 
length to induce the removal of the attenuator from the 
functional nucleic acid and permit the functional nucleic 
acid to achieve its active conformation. In one embodiment, 
the regulating nucleic acid is greater in length than the 
attenuator. Preferably, the regulating nucleic acid is at least 
about 5 to about 200 base pairs, more preferably from about 
10 to about 100 base pairs, and most preferably from about 
8 to about 30 base pairs in length. The regulating nucleic 
acid is preferably designed to bind speci?cally to a regulat 
ing nucleic acid target. 
In one embodiment, the regulating nucleic acid is an 
antisense nucleic acid. Antisense nucleic acids bind speci? 
cally to target complementary nucleic acid molecules. Alter 
natively, the regulating nucleic acid is an aptamer capable of 
speci?cally binding a target. Preferably, the functional 
nucleic acid is contiguous With the regulating nucleic acid. 
In another embodiment, the regulating nucleic acid is not 
contiguous With the functional nucleic acid and may be 
located, for example, on an expression vector that expresses 
a nucleic acid or protein, Which directly interacts With the 
functional nucleic acid. 
In a preferred embodiment of the invention the attenuator 
is an oligonucleotide nucleic acid sequence from about 3 to 
about 15 base pairs, more preferably from about 5 to 10 base 
pairs, and most preferably from about 6 to about 8 base pairs 
in length. In one embodiment, the attenuator binds to the 
functional nucleic acid and forms a duplex With feWer 
Watson-Crick base pairs than the duplex formed betWeen the 
regulating nucleic acid and regulating nucleic acid target. 
The energy of the regulating nucleic acid/regulating nucleic 
acid target duplex overWhelms the energy of the attenuator/ 
functional nucleic acid duplex, forcing removal of the 
attenuator from the functional nucleic acid. The attenuator 
free functional nucleic acid can then assume its active, 
three-dimensional conformation. 
In the absence of the regulating nucleic acid target, the 
attenuator preferably remains bound to the functional 
nucleic acid. In one embodiment, the attenuator is an 
aptamer or other nucleic acid sequence that binds or is 
complementary to at least a portion of the functional nucleic 
acid. Alternatively, the attenuator is a protein or compound 
capable of speci?cally binding to the functional nucleic acid. 
In one embodiment of the invention, the attenuator is 
bound only to the functional nucleic acid and does not bind 
to or overlap With any portion of the regulating nucleic acid. 
If the attenuator Were instead to overlap With both the 
functional nucleic acid and the regulating nucleic acid, it 
must be removed from (1) the regulating nucleic acid by 
strand displacement and (2) from the functional nucleic acid 
by the induced structural change in the probe. Such an 
overlapping attenuator must be designed to bind to both the 
functional nucleic acid and the regulating nucleic acid, thus 
limiting the available combinations of compatible functional 
nucleic acids and regulating nucleic acids. For example, an 
attenuator that is 1/3 complementary to the regulating nucleic 
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acid and 2/3 complementary to the functional nucleic acid 
Would require both strand displacement of 1/3 of the attenu 
ator from the regulating nucleic acid and the formation of a 
regulating nucleic acid/target duplex to induce the remaining 
2/3 of the attenuator from the functional nucleic acid. Fur 
thermore, the overlapping region Would have to be located 
in a “hot spot” subject to binding the regulating nucleic acid 
target When the regulating target is folded further limiting 
the compatible regulating nucleic acids available for use 
With a functional nucleic acid/attenuator combination. The 
modular nature of the preferred functional nucleic acid 
probes permits any functional nucleic acid to be used With 
virtually any regulating nucleic acid. Thus, removal of the 
attenuator is induced solely by the formation of a duplex 
betWeen the regulating nucleic acid and the regulating 
nucleic acid target. 
It is to be understood that the application of the teachings 
of the present invention to a speci?c problem or environ 
ment Will be Within the capabilities of one having ordinary 
skill in the art in light of the teachings contained herein. An 
exemplary product of the present invention and processes 
for its use appear in the folloWing Example. 
EXAMPLE 1 
The folloWing example illustrates the construction and 
method of using an exemplary functional nucleic acid probe 
made in accordance With the invention. A functional nucleic 
acid probe comprising a DNA-ATP aptamer (CCTGGGG 
GAGTATTGCGGAGGAAGGG)(SEQ ID NO: 1), an anti 
sense nucleic acid (TACTCCTCAGGGCCGGCGG)(SEQ 
ID NO: 2), and an attenuator (CCGCAATA)(SEQ ID NO: 3) 
is provided (FIG. 1). The DNA-ATP aptamer has a high 
af?nity for the nucleotide adenosine When it is in its active 
conformation. The antisense nucleic acid is complementary 
to a segment of the RAS oncogene mRNA (ATGAG 
GAGTCCCGGCCGCC)(SEQ ID NO: 4). The attenuator is 
an eight base pair oligonucleotide complementary to a 
region of DNA-ATP aptamer. In the absence of the RAS 
oncogene mRNA, the attenuator is bound to the DNA-ATP 
aptamer and maintains the DNA-ATP aptamer in its inactive 
conformation (FIG. 2). In the presence of the RAS oncogene 
mRNA, the antisense nucleic acid forms a duplex With the 
RAS oncogene mRNA (FIG. 3). The binding energy of the 
antisense nucleic acid/mRNA duplex overWhelms the bind 
ing energy of the DNA-ATP aptamer/attenuator duplex, 
forcing the attenuator off of the DNA-ATP aptamer. The 
DNA-ATP aptamer is noW able to achieve its active con 
formation and bind to adenosine. 
FIG. 4 demonstrates that the probe containing a DNA 








the presence of the RAS oncogene DNA oligonucleotide. 
With reference to FIG. 4, functional nucleic acid probe 1 Was 
passed through an adenosine-sepharose column in the pres 
ence (solid bars) or absence (open bars) of the RAS onco 
gene DNA oligonucleotide in four separate experiments. 
The functional nucleic acid probe Was radiolabeled With P32 
by end labeling With polynucleotide kinase. The samples 
Were normaliZed to the total amount of P32 labeled DNA 
loaded on to the column. The amount of the functional 
nucleic acid probe bound to the column in the presence or 
absence of the RAS oncogene DNA oligonucleotide is 
expressed as a fraction of the binding activity achieved When 
a DNA-ATP aptamer Was loaded on the same column. The 
functional nucleic acid probe Was 80% as active as the 
DNA-ATP aptamer When the probe Was loaded on the 
column after hybridiZation With the RAS oncogene DNA 
oligonucleotide. In contrast, the aptamer in the probe 
remained virtually inactive in the absence of the nucleic acid 
target. The speci?city of the interaction betWeen the aptamer 
and the adenosine-sepharose column Was demonstrated by 
passing the functional nucleic acid probe through a column 
having adenosine With a free N6 position. The DNA-ATP 
aptamer is speci?c for N8 compared With N6 linked adenos 
ine. The dashed line indicates that the DNA-ATP aptamer 
remained inactive When passed through an N6 linked 
adenosine column. 
FIG. 5 shoWs a linear relationship betWeen the amount of 
RAS oncogene DNA oligonucleotide added and the activity 
of the DNA-ATP aptamer in the functional nucleic acid 
probe. As the amount of RAS oncogene DNA oligonucle 
otide is increased from 0.1 uM to 1 uM, the activity of the 
DNA-ATP aptamer in the probe increases from approxi 
mately 0.4 to 0.8. The DNA-ATP aptamer of the functional 
nucleic acid probe is expressed relative to the activity of a 
DNA-ATP aptamer loaded on the column. The dashed line 
shoWs that a negligible amount of the DNA-ATP aptamer 
remained bound to the column in the absence of the RAS 
oncogene DNA oligonucleotide. 
The above description is only illustrative of preferred 
embodiments Which achieve the objects, features, and 
advantages of the present invention, and it is not intended 
that the present invention be limited thereto. Any modi?ca 
tions of the present invention Which come Within the spirit 
and scope of the folloWing claims is considered part of the 
present invention. For example, functional nucleic acid 
probes can be used to detect nucleic acid sequences that are 
deposited on solid surfaces (e.g., Northern, Southern, and 
Matrix Arrays) or used in capture assays such as the ELISA 
method. 
SEQUENCE LISTING 







SEQ ID NO 1 
LENGTH: 26 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
DNA-ATP aptamer 
<400> SEQUENCE: 1 






Cctgggggag tattgcggag gaaggg 
SEQ ID NO 2 
LENGTH: 19 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
antisense nucleic acid 
SEQUENCE: 2 
tactcctcag ggccqqcqq 
SEQ ID NO 3 
LENGTH: 8 
TYPE: DNA 





SEQ ID NO 4 
LENGTH: 19 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
segment of the RAS oncogene mRNA 
SEQUENCE: 4 
atgaggagtc ccggccgcc 
SEQ ID NO 5 
LENGTH: 53 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
SEQUENCE: 5 
cctgggggag tattgcggag gaagggtact cctcagggcc ggcggccgca 
26 
OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
19 
OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
19 
OTHER INFORMATION: Description of Artificial Sequence: Probe 
ata 53 
What is claimed as new and desired to be protected by 50 
Letters Patent of the United States is: 
1. Amethod of activating a functional nucleic acid to bind 
to a functional nucleic acid target comprising: 
providing at least one functional nucleic acid, at least one 
regulating nucleic acid, and at least one attenuator 
Wherein said functional nucleic acid is maintained in an 
inactive state by said attenuator, said attenuator does 
not bind to said regulating nucleic acid, and said 
regulating nucleic acid forms a loop structure betWeen 60 
said functional nucleic acid and said attenuator; 
55 
Wherein said regulating nucleic acid binds to a regulating 
nucleic acid target, Wherein binding of said regulating 
nucleic acid to said regulating nucleic acid target 
induces removal of said attenuator from said functional 
nucleic acid and activates said functional nucleic acid; 
and 
65 
Wherein said activated functional nucleic acid binds to 
said functional nucleic acid target. 
2. The method of claim 1, Wherein said functional nucleic 
acid is DNA. 
3. The method of claim 1, Wherein said functional nucleic 
acid is RNA. 
4. The method of claim 1, Wherein said functional nucleic 
acid is an aptamer. 
5. The method of claim 1, Wherein said functional nucleic 
acid is a riboZyme. 
6. The method of claim 1, Wherein said regulating nucleic 
acid is an antisense nucleic acid. 
7. The method of claim 1, Wherein said regulating nucleic 
acid target is a nucleic acid. 
8. The method of claim 1, Wherein said regulating nucleic 
acid is an aptamer. 
US 7,115,369 B2 
13 
9. The method of claim 1, wherein said regulating nucleic 
acid target is selected from the group consisting of nucleic 
acid, protein, and a chemical compound. 
10. The method of claim 1, Wherein said functional 
nucleic acid, said regulating nucleic acid, and said attenuator 
are arranged in cis. 
11. The method of claim 1, Wherein said functional 
nucleic acid, said regulating nucleic acid, and said attenuator 
are contiguous. 
12. The method of claim 1, Wherein the length of said 
regulating nucleic acid is greater than the length of said 
attenuator. 
13. The method of claim 1, Wherein said regulating 
nucleic acid is from about 5 to about 100 base pairs. 
14 
14. The method of claim 12, Wherein said regulating 
nucleic acid is from about 8 to about 30 base pairs. 
15. The method of claim 1, Wherein said attenuator is 
from about 3 to about 15 base pairs. 
16. The method of claim 14, Wherein said attenuator is 
from about 6 to about 8 base pairs. 
17. The method of claim 1, Wherein binding energy 
generated by binding of said regulating nucleic acid to said 
regulating nucleic acid target is greater than binding energy 
generated by the binding of said attenuator to said functional 
nucleic acid. 
